Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma

Makoto Nakano, Chiharu Sogawa, Norio Sogawa, Katsuaki Mishima, Eiki Yamachika, Nobuyoshi Mizukawa, Joji Fukunaga, Tomoaki Kawamoto, Koichi Sawaki, Toshio Sugahara, Hiroaki Furuta

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Cisplatin (CDDP) is a useful drug for the treatment of malignant solid tumors of the head and neck. Because CDDP includes the heavy metal platinum as a component, it is thought metallothionein (MT) may be involved in CDDP-resistance. However, functional differences between the four MT isoforms (MT-I, II, III and IV) remain unclear. The aim of this study was to investigate the relationship between MT isoform expression and CDDP-resistance. Two human tongue squamous cell carcinoma cell lines not exposed to anticancer chemotherapy were studied. The cell lines were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis before and after CDDP-treatment. Both cell lines expressed MT-I/II and MT-IV isoforms but not the MT-III isoform. Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line. Our results showed that expression of the MT I/II isoform was induced by CDDP treatment, and may play an important role in CDDP-resistance in squamous cell carcinoma of the human tongue.

Original languageEnglish
Pages (from-to)299-303
Number of pages5
JournalAnticancer research
Issue number1 A
Publication statusPublished - Jan 2003


  • Cell line
  • Experimental study
  • Human
  • In vitro
  • Metallothionein isoforms
  • Squamous cell carcinoma
  • Tongue

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this